Melanoma under 40

By Carole Renouf
17 November 2016
I spent a morning in clinic with one of MIA’s surgeons about a month ago. As each of her patients arrived, she inquired whether they would mind the CEO sitting in on their appointment because the CEO wanted to learn more about the experience of patients. Every single patient consented to having me present. They ranged from old to young, male to female, early to advanced melanoma and it was very moving for me to spend some time with them as they received everything from the worst news to the best. All the people with melanoma I met that day have stayed with me, but none more so than the young ones (under 40). It was the statistic that melanoma is the most common cancer in 15-39 year old Australians that really persuaded me to take this job.
A few years ago, when I was in a previous role, one of my proudest initiatives was the work we did reaching out to young women, those who got breast cancer in their 20s and 30s.
The impact of cancer on young lives is ferocious and wide-ranging. This is not to diminish in any way its significant impact on older lives, but when you are under 40 the experience of cancer tends to take more away across more aspects of your life and over a longer time. Also, as cancer services tend to be geared towards older people, you are likely to find less help and support suited to your needs and life stage.
The qualitative research that was done into breast cancer in young women revealed that the disease, diagnosis and treatment impacted issues as critical as future employment and career, finances, fertility, relationships and sexuality and self-image. If you would like to see footage from the press conference with affected young women, click here.
To my knowledge, no such research has yet been done in melanoma in Australia. Melanoma is the most common cause of cancer death in 20-39 year olds. In contrast to breast cancer, melanoma strikes both men and women (slightly more men) and therefore must assuredly involve additional issues to breast cancer. Yet, there is no body of evidence as to what these are, nor how to address them.
As we head towards 2017, I have set myself the goal of gathering the evidence from young Australians affected by melanoma of its impact on their lives and of any unmet needs they may have. This may mean a shift in the way we and others provide services.
For example, over 90% of melanoma – if caught early – is curable through surgery, so surgery remains a dominant treatment modality. A famous surgeon once said, “If you can’t cut it out, it’s not real” - yet studies show that psychosocial distress is very real in at least 30% of melanoma patients and I suspect even more real in the young. So is there an unmet need for more psychosocial support for under 40s affected by melanoma, for example?
If you’d like to share your experience and help me gather the evidence about the impact of melanoma on young Australians, please contact us at projectyoung@melanoma.org.au for a personal interview. Your contribution would be greatly appreciated.

Australia unites taking small steps to make a big difference for melanoma research
Thank you to everyone involved in making Melanoma March 2016 a huge success

And they're off... Melanoma March 2016 begins!
Melanoma March 2016 has officially begun with more than 300 people marching in Rockingham and Devonport.

5 Minutes with Carole Renouf
MIA's new CEO Carole Renouf has been in her role only a month, but is already making plans for the future of MIA.

Opinion: Outing Melanoma
In the wake of Susie Maroney's recent announcement that she is battling melanoma, CEO Carole Renouf's opinion piece weighs in on the critical need we have in Australia to raise awareness about melanoma.

Congratulations Professor Georgina Long
MIA's Georgina Long has been appointed Professor and awarded a coverted prize in medial research.

Melanoma March 2016: Where your funds are going
Melanoma March 2016 funding will be used to initiate an ambitious new project that will support the best possible care for melanoma patients around Australia through a new data and communication platform.

New research shows long-term survival in group of advanced melanoma patients treated with BRAF inhibitors
New MIA-led research has been published in the Journal of Clinical Oncology.

Melanoma March 2016 is launched
Melanoma March was officially launched today with the announcement of the national research project funded by the march.

MIA's research pivotal in TGA's approval of new therapy
Clinical research undertaken at MIA has been pivotal in supporting the recent Therapeutic Goods Administration approval of Opdivo (nivolumab) for advanced melanoma.

The Face of Melanoma March
Maddison, the face of our Melanoma March campaign, knows the far-reaching effects that melanoma can have.

Q&A With An Expert: Dermatologist
MIA's Dermatologist Associate Professor Pascale Guitera answers your most commonly-asked questions about sunscreen.

New figures show melanoma most common cancer in young Queenslanders
Statistics released by the Queensland Cancer Registry have revealed that melanoma is the most common cancer in young Queenslanders aged under 35, with rates in young women more than 20 per cent higher than in men.

5 minutes with Associate Professor Georgina Long
As 2015 draws to a close, we took the opportunity to speak with Associate Professor Georgina Long to discuss her crucial role at Melanoma Institute Australia, and the current research projects she is working on.

Watch Your Mate's Back: helping young Australians recognise melanoma
MIA’s annual summer awareness campaign, which launched today (1 December), is reminding Australians how to protect themselves from the sun while highlighting the importance of encouraging friends, partners and family to do the same.

Your Guide to Early Melanoma patient information packs
Your Guide to Early Melanoma is a new patient information pack to offer additional information for those affected by melanoma.

Clinicians invited to MIA's 'World Round Up' event
Special Event to share advances in diagnosis and treatment of both early and late stage melanoma

Melanoma landmark study to help further develop personalised cancer treatment
MIA researchers contribute to the discovery of ‘treasure trove’ of information leading to more targeted treatments for melanoma

Sunrise features inspiring story of MIA patient
Melanoma Institute Australia (MIA) patient Tara Moran and her seven year old daughter Olivia, who is fundraising for MIA, have been in the national media spotlight this week.

Leading researchers honoured for global contribution to science and innovation
Melanoma Institute Australia’s (MIA’s) researchers have again been recognised, this time in the prestigious line-up for the 2015 Thomson Reuters Australian Citation & Innovation Awards.

MIA welcomes ground-breaking new PBS melanoma treatment
New Federal Government funding means patients with the most deadly form of melanoma, will soon be able to receive treatment with the drug Keytruda® (pembrolizumab), on the Pharmaceutical Benefits Scheme (PBS).